Acknowledgements The research was supported in part by the National Institutes of Health (R01-GM115622 and R01-CA207701 to J.W., R01-AG045183, R01-AT009050, R21-EB022302 and DP1-DK113644 to M.C.W., R01-GM120033 to M.M.-S., R01-NS100893 to M.X.), the Welch Foundation (Q-1912 to M.C.W.), Cancer Prevention and Research Institute of Texas (CPRIT R1104 to J.W., RP130573 to M.M.-S.), Whitehall Foundation Research Grant (2015-05-54 to M.X.), the Curtis Hankamer Basic Research Fund at Baylor College of Medicine (to M.X.), Caroline DeLuca Scholarship (to M.X.), the United States Department of Agriculture, Agricultural Research Service through Cooperative Agreement Number 58-6250-0-008 (to N.C.), the IDDRC Microscopy Core (P30HD024064 and 1U54 HD083092 Intellectual and Developmental Disabilities Research Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development), the Optical Imaging and Vital Microscopy core, and the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the NIH (AI036211, CA125123, and RR024574) and the expert assistance of Joel M

These treatments permanently reduce fat cells in areas that are resistant to diet and exercise, helping refine contours and enhance overall shape
BioRender users often use the L-cell (releasing GLP-1) icon in posters, grant applications, educational materials, and graphical abstracts
A 2025 article from SHRM reports a notable increase in the average representation of GLP-1 drugs used for weight loss in total annual claims for employers, increasing from 8.9 percent in 2024 to 10.5 percent in 2025
00:13:24 Vickie Danaher Also know how to handle missed doses
These initiatives remain early stage and are subject to meaningful scientific, clinical and regulatory uncertainty